Literature DB >> 24453387

Modeling Disease Progression with Longitudinal Markers.

Lurdes Y T Inoue1, Ruth Etzioni2, Christopher Morrell3, Peter Müller4.   

Abstract

In this paper we propose a Bayesian natural history model for disease progression based on the joint modeling of longitudinal biomarker levels, age at clinical detection of disease and disease status at diagnosis. We establish a link between the longitudinal responses and the natural history of the disease by using an underlying latent disease process which describes the onset of the disease and models the transition to an advanced stage of the disease as dependent on the biomarker levels. We apply our model to the data from the Baltimore Longitudinal Study of Aging on prostate specific antigen (PSA) to investigate the natural history of prostate cancer.

Entities:  

Keywords:  Markov Chain Monte Carlo methods; Natural history model; disease progression; latent variables; longitudinal response; prostate specific antigen

Year:  2008        PMID: 24453387      PMCID: PMC3896511          DOI: 10.1198/016214507000000356

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  26 in total

1.  The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure.

Authors:  Ngayee J Law; Jeremy M G Taylor; Howard Sandler
Journal:  Biostatistics       Date:  2002-12       Impact factor: 5.899

2.  Analysis of doubly-censored survival data, with application to AIDS.

Authors:  V De Gruttola; S W Lagakos
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

3.  Estimation of the duration of a pre-clinical disease state using screening data.

Authors:  S D Walter; N E Day
Journal:  Am J Epidemiol       Date:  1983-12       Impact factor: 4.897

4.  Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.

Authors:  N E Day; S D Walter
Journal:  Biometrics       Date:  1984-03       Impact factor: 2.571

5.  Reconstruction and future trends of the AIDS epidemic in the United States.

Authors:  R Brookmeyer
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

6.  Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values.

Authors:  E D Crawford; S Leewansangtong; S Goktas; K Holthaus; M Baier
Journal:  Prostate       Date:  1999-03-01       Impact factor: 4.104

7.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

8.  Statistical analysis of the stages of HIV infection using a Markov model.

Authors:  I M Longini; W S Clark; R H Byers; J W Ward; W W Darrow; G F Lemp; H W Hethcote
Journal:  Stat Med       Date:  1989-07       Impact factor: 2.373

9.  Nonparametric estimation of the size-metastasis relationship in solid cancers.

Authors:  M Kimmel; B J Flehinger
Journal:  Biometrics       Date:  1991-09       Impact factor: 2.571

10.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

Authors:  P H Gann; C H Hennekens; M J Stampfer
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

View more
  10 in total

1.  Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.

Authors:  Roman Gulati; Lurdes Inoue; Jeffrey Katcher; William Hazelton; Ruth Etzioni
Journal:  Biostatistics       Date:  2010-06-07       Impact factor: 5.899

2.  Screening for prostate cancer using multivariate mixed-effects models.

Authors:  Christopher H Morrell; Larry J Brant; Shan Sheng; E Jeffrey Metter
Journal:  J Appl Stat       Date:  2012-06-01       Impact factor: 1.404

3.  Deriving benefit of early detection from biomarker-based prognostic models.

Authors:  L Y T Inoue; R Gulati; C Yu; M W Kattan; R Etzioni
Journal:  Biostatistics       Date:  2012-06-22       Impact factor: 5.899

4.  Screening for prostate cancer in the US? Reduce the harms and keep the benefit.

Authors:  Tiago M de Carvalho; Eveline A M Heijnsdijk; Harry J de Koning
Journal:  Int J Cancer       Date:  2014-09-01       Impact factor: 7.396

5.  Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Authors:  Reka Pataky; Roman Gulati; Ruth Etzioni; Peter Black; Kim N Chi; Andrew J Coldman; Tom Pickles; Scott Tyldesley; Stuart Peacock
Journal:  Int J Cancer       Date:  2014-02-04       Impact factor: 7.396

6.  What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.

Authors:  Roman Gulati; Elisabeth M Wever; Alex Tsodikov; David F Penson; Lurdes Y T Inoue; Jeffrey Katcher; Shih-Yuan Lee; Eveline A M Heijnsdijk; Gerrit Draisma; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05       Impact factor: 4.254

7.  A Bivariate Mixed-Effects Location-Scale Model with application to Ecological Momentary Assessment (EMA) data.

Authors:  Oksana Pugach; Donald Hedeker; Robin Mermelstein
Journal:  Health Serv Outcomes Res Methodol       Date:  2014-12

8.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

9.  Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.

Authors:  Ruth Etzioni; Isabelle Durand-Zaleski; Iris Lansdorp-Vogelaar
Journal:  J Natl Cancer Inst Monogr       Date:  2013

10.  Repeated measures discriminant analysis using multivariate generalized estimation equations.

Authors:  Anita Brobbey; Samuel Wiebe; Alberto Nettel-Aguirre; Colin Bruce Josephson; Tyler Williamson; Lisa M Lix; Tolulope T Sajobi
Journal:  Stat Methods Med Res       Date:  2021-12-13       Impact factor: 3.021

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.